{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T01:09:55Z","timestamp":1744074595654},"reference-count":65,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2013.0793","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:25:18Z","timestamp":1525253118000},"source":"Crossref","is-referenced-by-count":4,"title":["Targeted Vaccine Selection in Influenza Vaccination"],"prefix":"10.3238","author":[{"given":"Peter","family":"Wutzler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Knuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Wahle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2013,11,22]]},"reference":[{"key":"10.3238\/arztebl.2013.0793_ref1","unstructured":"Pfleiderer M: Pr\u00e4vention\/Impfen. In: Zepp F, Ruf BR (eds.): H1N1-Update 2009: Kompendium Influenza 2009. Wiesbaden: med update 2009."},{"key":"10.3238\/arztebl.2013.0793_ref2","doi-asserted-by":"crossref","unstructured":"Belshe RB: The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28: 45\u201353.","DOI":"10.1016\/j.vaccine.2010.08.028"},{"key":"10.3238\/arztebl.2013.0793_ref3","doi-asserted-by":"crossref","unstructured":"Keitel WA, Atmar RL, Cate TR, et al.: Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006: 166: 1121\u20137.","DOI":"10.1001\/archinte.166.10.1121"},{"key":"10.3238\/arztebl.2013.0793_ref4","doi-asserted-by":"crossref","unstructured":"Couch RB, Winokur P, Brady R, et al.: Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25: 7656\u201363.","DOI":"10.1016\/j.vaccine.2007.08.042"},{"key":"10.3238\/arztebl.2013.0793_ref5","doi-asserted-by":"crossref","unstructured":"Chen WH, Cross AS, Edelman R, Sztein MB, Blackwelder WC, Pasetti MF: Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011; 29: 2865\u201373.","DOI":"10.1016\/j.vaccine.2011.02.017"},{"key":"10.3238\/arztebl.2013.0793_ref6","unstructured":"Centers for Disease Control and Prevention: Licensure of a high-dose inactivated influenza vaccine for persons aged > or = 65 years (Fluzone High-Dose) and guidance for use \u2013 United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 485\u20136."},{"key":"10.3238\/arztebl.2013.0793_ref7","doi-asserted-by":"crossref","unstructured":"Heinonen S, Silvennoinen H, Lehtinen P, Vainionp\u00e4\u00e4 R, Ziegler T, Heikkinen: Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011; 11: 23\u20139.","DOI":"10.1016\/S1473-3099(10)70255-3"},{"key":"10.3238\/arztebl.2013.0793_ref8","doi-asserted-by":"crossref","unstructured":"Song JY, Cheong HJ, Seo YB, et al.: Comparison of the long-term immunogenicity of two pandemic influenza A\/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. Clin Vaccine Immunol 2012; 19: 638\u201341.","DOI":"10.1128\/CVI.00026-12"},{"key":"10.3238\/arztebl.2013.0793_ref9","doi-asserted-by":"crossref","unstructured":"Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G: A randomized clinical trial to identify the optimal antigen and MF59(\u00ae) adjuvant dose of a monovalent A\/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 2012; 30: 70\u20137.","DOI":"10.1016\/j.vaccine.2012.03.017"},{"key":"10.3238\/arztebl.2013.0793_ref10","doi-asserted-by":"crossref","unstructured":"Podda A: The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673\u201380.","DOI":"10.1016\/S0264-410X(00)00499-0"},{"key":"10.3238\/arztebl.2013.0793_ref11","doi-asserted-by":"crossref","unstructured":"Banzhoff A, Nacci P, Podda A: A new MF-59 adjuvanted vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49: 177\u201384.","DOI":"10.1159\/000069172"},{"key":"10.3238\/arztebl.2013.0793_ref12","doi-asserted-by":"crossref","unstructured":"Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga: MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18\u201360 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007; 25: 3955\u201361.","DOI":"10.1016\/j.vaccine.2007.02.045"},{"key":"10.3238\/arztebl.2013.0793_ref13","doi-asserted-by":"crossref","unstructured":"Del Giudice G, Hilbert AK, Bugarini R, et al.: An MF59-adjuvanted inactivated influenza vaccine containing A\/Panama\/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A\/Fujian\/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24: 3063\u20135.","DOI":"10.1016\/j.vaccine.2006.01.015"},{"key":"10.3238\/arztebl.2013.0793_ref14","doi-asserted-by":"crossref","unstructured":"Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R: Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007; 27: 542\u20137.","DOI":"10.1007\/s10875-007-9100-4"},{"key":"10.3238\/arztebl.2013.0793_ref15","doi-asserted-by":"crossref","unstructured":"Puig-Barber\u00e0 J, Diez-Domingo J, Hoyos SP, Varea AB, Vidal DG: Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 2004; 23: 283\u20139.","DOI":"10.1016\/j.vaccine.2004.07.017"},{"key":"10.3238\/arztebl.2013.0793_ref16","doi-asserted-by":"crossref","unstructured":"Puig-Barber\u00e0 J, D\u00edez-Domingo J, Varea AB, et al.: Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007; 25: 7313\u201321.","DOI":"10.1016\/j.vaccine.2007.08.039"},{"key":"10.3238\/arztebl.2013.0793_ref17","doi-asserted-by":"crossref","unstructured":"Mannino S, Villa M, Apolone G, et al.: Effectiveness of adjuvanted influenza vaccination in elderly subjects in Northern Italy. Am J Epidemiol 2012; 176: 527\u201333.","DOI":"10.1093\/aje\/kws313"},{"key":"10.3238\/arztebl.2013.0793_ref18","doi-asserted-by":"crossref","unstructured":"Vesikari T, Pellegrini M, Karvonen A, et al.: Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28: 563\u201371.","DOI":"10.1097\/INF.0b013e31819d6394"},{"key":"10.3238\/arztebl.2013.0793_ref19","doi-asserted-by":"crossref","unstructured":"Vesikari T, Knuf M, Wutzler P, et al.: Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365: 1406\u201316.","DOI":"10.1056\/NEJMoa1010331"},{"key":"10.3238\/arztebl.2013.0793_ref20","doi-asserted-by":"crossref","unstructured":"Huckriede A, Bungener L, Stegmann T, et al.: The virosome concept for influenza vaccines. Vaccine 2005; 23: 26\u201338.","DOI":"10.1016\/j.vaccine.2005.04.026"},{"key":"10.3238\/arztebl.2013.0793_ref21","doi-asserted-by":"crossref","unstructured":"Conne P, Gauthey L, Vernet P, et al.: Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997; 15: 1675\u20139.","DOI":"10.1016\/S0264-410X(97)00087-X"},{"key":"10.3238\/arztebl.2013.0793_ref22","doi-asserted-by":"crossref","unstructured":"de Bruijn IA, Nauta J, Gerez L, Palache A: Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004; 103: 139\u201345.","DOI":"10.1016\/j.virusres.2004.02.026"},{"key":"10.3238\/arztebl.2013.0793_ref23","doi-asserted-by":"crossref","unstructured":"Herzog C, Metcalfe IC, Schaad UB: Virosome influenza vaccine in children. Vaccine 2002; 20: 24\u20138.","DOI":"10.1016\/S0264-410X(02)00508-X"},{"key":"10.3238\/arztebl.2013.0793_ref24","doi-asserted-by":"crossref","unstructured":"de Bruijn IA, Nauta J, Gerez L, Palache AM: The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad) in elderly subjects. Vaccine 2006; 24: 6629\u201331.","DOI":"10.1016\/j.vaccine.2006.05.035"},{"key":"10.3238\/arztebl.2013.0793_ref25","doi-asserted-by":"crossref","unstructured":"Baldo V, Baldovin T, Pellegrini M, et al.: Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010: 517198.","DOI":"10.1155\/2010\/517198"},{"key":"10.3238\/arztebl.2013.0793_ref26","doi-asserted-by":"crossref","unstructured":"Salleras L, Dom\u00ednguez A, Pumarola T, et al.: Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3\u201314 years: a prospective cohort study. Vaccine 2006; 24: 6638\u201342.","DOI":"10.1016\/j.vaccine.2006.05.034"},{"key":"10.3238\/arztebl.2013.0793_ref27","doi-asserted-by":"crossref","unstructured":"van Damme P, Arnou R, Kafeja F, et al.: Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10: 134.","DOI":"10.1186\/1471-2334-10-134"},{"key":"10.3238\/arztebl.2013.0793_ref28","doi-asserted-by":"crossref","unstructured":"Ansaldi F, Canepa P, Ceravolo A, et al.: Intanza(\u00ae) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 2012; 30: 2908\u201313.","DOI":"10.1016\/j.vaccine.2012.02.003"},{"key":"10.3238\/arztebl.2013.0793_ref29","doi-asserted-by":"crossref","unstructured":"Belshe RB, Gruber WC, Mendelman PM, et al.: Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133\u20137.","DOI":"10.1086\/315323"},{"key":"10.3238\/arztebl.2013.0793_ref30","doi-asserted-by":"crossref","unstructured":"Hoft DF, Babusis E, Worku S, et al.: Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204: 845\u201353.","DOI":"10.1093\/infdis\/jir436"},{"key":"10.3238\/arztebl.2013.0793_ref31","doi-asserted-by":"crossref","unstructured":"Ashkenazi S, Vertruyen A, Ar\u00edstegui J, et al.: CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 118: 2298\u2013312.","DOI":"10.1097\/01.inf.0000237829.66310.85"},{"key":"10.3238\/arztebl.2013.0793_ref32","doi-asserted-by":"crossref","unstructured":"Fleming DM, Crovari P, Wahn U, et al.: Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25: 860\u20139.","DOI":"10.1097\/01.inf.0000237797.14283.cf"},{"key":"10.3238\/arztebl.2013.0793_ref33","doi-asserted-by":"crossref","unstructured":"Belshe RB, Edwards KM, Vesikari, et al.: Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356: 685\u201396.","DOI":"10.1056\/NEJMoa065368"},{"key":"10.3238\/arztebl.2013.0793_ref34","doi-asserted-by":"crossref","unstructured":"Belshe RB, Toback SL, Yi T, Ambrose CS: Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respi Viruses 2010; 4: 141\u20135.","DOI":"10.1111\/j.1750-2659.2009.00124.x"},{"key":"10.3238\/arztebl.2013.0793_ref35","doi-asserted-by":"crossref","unstructured":"Osterholm MT, Kelley NS, Sommer A, Belongia EA: Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 36\u201344.","DOI":"10.1016\/S1473-3099(11)70295-X"},{"key":"10.3238\/arztebl.2013.0793_ref36","doi-asserted-by":"crossref","unstructured":"Ambrose CS, Wu X, Knuf M, Wutzler P: The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine 2012; 30: 886\u201392.","DOI":"10.1016\/j.vaccine.2011.11.104"},{"key":"10.3238\/arztebl.2013.0793_ref37","doi-asserted-by":"crossref","unstructured":"Belshe RB, Gruber WC, Mendelman PM, et al.: Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A\/Sydney) not contained in the vaccine. J Pediatr 2000; 136: 168\u201375.","DOI":"10.1016\/S0022-3476(00)70097-7"},{"key":"10.3238\/arztebl.2013.0793_ref38","doi-asserted-by":"crossref","unstructured":"Block SL, Heikkinen T, Toback SL, Zheng W, Ambrose CS: The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011; 30: 203\u20137.","DOI":"10.1097\/INF.0b013e3181faac7c"},{"key":"10.3238\/arztebl.2013.0793_ref39","doi-asserted-by":"crossref","unstructured":"Belshe RB, Ambrose CS, Yi T: Safety and efficacy of live attenuated influenza vaccine in children 2\u20137 years of age. Vaccine 2008; 26: 10\u20136.","DOI":"10.1016\/j.vaccine.2008.06.083"},{"key":"10.3238\/arztebl.2013.0793_ref40","doi-asserted-by":"crossref","unstructured":"Hilleman MR: Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002; 20: 3068\u201387.","DOI":"10.1016\/S0264-410X(02)00254-2"},{"key":"10.3238\/arztebl.2013.0793_ref41","unstructured":"Robert Koch-Institut: Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut\/Stand: Juli 2012. ."},{"key":"10.3238\/arztebl.2013.0793_ref42","doi-asserted-by":"crossref","unstructured":"Beyer WE, Palache AM, Osterhaus AD: Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and meta-analysis of the literature. Clin Drug Investig 1998; 15: 1\u201312.","DOI":"10.2165\/00044011-199815010-00001"},{"key":"10.3238\/arztebl.2013.0793_ref43","unstructured":"Anonymus: Erster Quadrivalenter Grippeimpfstoff. Dtsch Arztebl 2013; 110(12): A 569. (Pharmainformation)"},{"key":"10.3238\/arztebl.2013.0793_ref44","doi-asserted-by":"crossref","unstructured":"Uphoff H, Hauri AM, Schweiger B, et al.: Zur Sch\u00e4tzung der Schutzwirkung der Influenzaimpfung aus Surveillancedaten. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006; 49: 287\u201395.","DOI":"10.1007\/s00103-006-1233-8"},{"key":"10.3238\/arztebl.2013.0793_ref45","doi-asserted-by":"crossref","unstructured":"Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V: Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; 2: CD004879.","DOI":"10.1002\/14651858.CD004879.pub3"},{"key":"10.3238\/arztebl.2013.0793_ref46","doi-asserted-by":"crossref","unstructured":"Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S: A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011; 29: 9159\u201370.","DOI":"10.1016\/j.vaccine.2011.08.008"},{"key":"10.3238\/arztebl.2013.0793_ref47","doi-asserted-by":"crossref","unstructured":"Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7: CD001269. \/td>","DOI":"10.1002\/14651858.CD001269.pub4"},{"key":"10.3238\/arztebl.2013.0793_ref48","doi-asserted-by":"crossref","unstructured":"Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE: Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; 2: CD004876.","DOI":"10.1002\/14651858.CD004876.pub3"},{"key":"10.3238\/arztebl.2013.0793_ref49","doi-asserted-by":"crossref","unstructured":"DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK: High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009\u20132010 season. Vaccine 2013; 31: 861\u20136.","DOI":"10.1016\/j.vaccine.2012.12.013"},{"key":"10.3238\/arztebl.2013.0793_ref50","doi-asserted-by":"crossref","unstructured":"Leroux-Roels I, Borkowski A, Vanwolleghem T, et al.: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370: 580\u20139","DOI":"10.1016\/S0140-6736(07)61297-5"},{"key":"10.3238\/arztebl.2013.0793_ref51","doi-asserted-by":"crossref","unstructured":"Schwarz TF, Horacek T, Knuf M, et al.: Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27: 6284\u201390.","DOI":"10.1016\/j.vaccine.2009.01.040"},{"key":"10.3238\/arztebl.2013.0793_ref52","doi-asserted-by":"crossref","unstructured":"Nohynek H, Jokinen J, Partinen M, et al.: AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7: e33536.","DOI":"10.1371\/journal.pone.0033536"},{"key":"10.3238\/arztebl.2013.0793_ref53","doi-asserted-by":"crossref","unstructured":"Partinen M, Saarenp\u00e4\u00e4-Heikkil\u00e4 O, Ilveskoski I, et al.:Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012; 7: e33723.","DOI":"10.1371\/journal.pone.0033723"},{"key":"10.3238\/arztebl.2013.0793_ref54","doi-asserted-by":"crossref","unstructured":"Miller E, Andrews N, Stellitano L, et al.: Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346: 794.","DOI":"10.1136\/bmj.f794"},{"key":"10.3238\/arztebl.2013.0793_ref55","doi-asserted-by":"crossref","unstructured":"Tsai TF, Crucitti A, Nacci P, et al.: Explorations of clinical trials and pharmacovigilance databases of MF59\u00ae-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; 43: 702\u20136.","DOI":"10.3109\/00365548.2011.580777"},{"key":"10.3238\/arztebl.2013.0793_ref56","doi-asserted-by":"crossref","unstructured":"Choe YJ, Bae GR, Lee DH: No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: an ecological study. Vaccine 2012; 30: 7439\u201342.","DOI":"10.1016\/j.vaccine.2012.10.030"},{"key":"10.3238\/arztebl.2013.0793_ref57","unstructured":"Esposito S, Marchisio P, Montinaro V, et al.:The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥ 6 to"},{"key":"10.3238\/arztebl.2013.0793_ref58","doi-asserted-by":"crossref","unstructured":"Nicolas JF, Guy B: Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7: 1201\u201314.","DOI":"10.1586\/14760584.7.8.1201"},{"key":"10.3238\/arztebl.2013.0793_ref59","doi-asserted-by":"crossref","unstructured":"Lambert PH, Laurent PE: Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008; 26: 3197\u2013208.","DOI":"10.1016\/j.vaccine.2008.03.095"},{"key":"10.3238\/arztebl.2013.0793_ref60","doi-asserted-by":"crossref","unstructured":"Leroux-Roels I, Vets E, Freese R, et al.: Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 2008; 26: 6614\u20139.","DOI":"10.1016\/j.vaccine.2008.09.078"},{"key":"10.3238\/arztebl.2013.0793_ref61","doi-asserted-by":"crossref","unstructured":"Holland D, Booy R, De Looze F, et al.: Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198: 650\u20138.","DOI":"10.1086\/590434"},{"key":"10.3238\/arztebl.2013.0793_ref62","doi-asserted-by":"crossref","unstructured":"Murphy BR, Coelingh K: Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002; 15: 295\u2013323.","DOI":"10.1089\/08828240260066242"},{"key":"10.3238\/arztebl.2013.0793_ref63","doi-asserted-by":"crossref","unstructured":"Jin H, Lu B, Zhou H, et al.: Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A\/Ann Arbor\/6\/60. Virology 2003; 306: 18\u201324.","DOI":"10.1016\/S0042-6822(02)00035-1"},{"key":"10.3238\/arztebl.2013.0793_ref64","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Korhonen T, et al.: A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25: 590\u20135.","DOI":"10.1097\/01.inf.0000220229.51531.47"},{"key":"10.3238\/arztebl.2013.0793_ref65","doi-asserted-by":"crossref","unstructured":"Ambrose CS, Wu X, Jones T, Mallory RM: The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 2012; 30: 6794\u2013801.","DOI":"10.1016\/j.vaccine.2012.09.018"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T14:15:12Z","timestamp":1638800112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,22]]},"references-count":65,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2013.0793","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,22]]}}}